ZERO WORLD RESEARCHアミノ酸・有機酸の学術文献データベース

The Effects of Oral l-Arginine and l-Citrulline Supplementation on Blood Pressure.

経口l-アルギニンおよびl-シトルリン補給が血圧に及ぼす影響 (機械翻訳の邦題)

Nutrients2019Khalaf D, Krüger M, Wehland M, et al.
研究デザインレビュー
対象ヒト

記録の確認項目

研究デザイン
レビュー
対象
ヒト
出版年
2019
出典
doi.org
抄録の表示
表示あり
出版状態
有効な記録
状態確認日
2026/08/17
収集日
2026/08/13
鮮度
確認期限内
確認段階
自動処理
記録状態
公開

日本語要約(機械生成)

本総説は、一酸化窒素(NO)の基質となるアミノ酸であるl-アルギニン(Arg)とl-シトルリン(Cit)の経口投与が、NO産生を増加させ血圧を低下させるか検討した。ArgとCitは血漿Arg濃度を上昇させ、Citは初回通過代謝が低いため約2倍の効果を示す。現在のデータでは、Arg補給は血圧を5.39/2.66 mmHg低下させ、食事改善や運動と同等の効果がある。Citの降圧効果は不明確だが、4.1/2.08〜7.54/3.77 mmHgと推定される。しかし、正常時の血漿Arg濃度はeNOSのKmを大きく上回るため、追加のArgがNO産生を増やすとは考えにくく、この矛盾は「l-アルギニンパラドックス」と呼ばれる。

この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。

抄録

Nitric oxide (NO) is a well-known vasodilator produced by the vascular endothelium via the enzyme endothelial nitric oxide synthase (eNOS). The inadequate production of NO has been linked to elevated blood pressure (BP) in both human and animal studies, and might be due to substrate inaccessibility. This review aimed to investigate whether oral administration of the amino acids l-arginine (Arg) and l-citrulline (Cit), which are potential substrates for eNOS, could effectively reduce BP by increasing NO production. Both Arg and Cit are effective at increasing plasma Arg. Cit is approximately twice as potent, which is most likely due to a lower first-pass metabolism. The current data suggest that oral Arg supplementation can lower BP by 5.39/2.66 mmHg, which is an effect that is comparable with diet changes and exercise implementation. The antihypertensive properties of Cit are more questionable, but are likely in the range of 4.1/2.08 to 7.54/3.77 mmHg. The exact mechanism by which Cit and Arg exert their effect is not fully understood, as normal plasma Arg concentration greatly exceeds the Michaelis constant (Km) of eNOS. Thus, elevated plasma Arg concentrations would not be expected to increase endogenous NO production significantly, but have nonetheless been observed in other studies. This phenomenon is known as the "l-arginine paradox".

MeSH

Administration, OralAntihypertensive AgentsArginineBlood PressureCitrullineHumansHypertension

DOI 10.3390/nu11071679

PMID 31336573

原文・出典を見る →